Comparative Pharmacology
Head-to-head clinical analysis: SITAGLIPTIN METFORMIN HYDROCHLORIDE versus SITAGLIPTIN PHOSPHATE METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SITAGLIPTIN METFORMIN HYDROCHLORIDE versus SITAGLIPTIN PHOSPHATE METFORMIN HYDROCHLORIDE.
SITAGLIPTIN; METFORMIN HYDROCHLORIDE vs SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sitagliptin is a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity via AMP-kinase activation.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and decreasing glucagon secretion. Metformin is a biguanide that reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
1 tablet orally twice daily; each tablet contains sitagliptin 50 mg and metformin hydrochloride 500 mg, 850 mg, or 1000 mg; maximum dose: sitagliptin 100 mg/day, metformin 2000 mg/day.
Oral, 50 mg sitagliptin/500 mg metformin twice daily or 50 mg sitagliptin/1000 mg metformin twice daily, individually titrated based on glycemic response and tolerability. Maximum daily dose: sitagliptin 100 mg, metformin 2000 mg.
None Documented
None Documented
Sitagliptin: terminal half-life 12.4 hours (healthy), prolonged in renal impairment (up to 28–39 hours in severe impairment). Metformin: terminal half-life 4–8.7 hours (healthy), prolonged in renal impairment (up to 17.6 hours in moderate impairment).
Sitagliptin: 12.4 h; metformin: 6.2 h (prolonged in renal impairment).
Sitagliptin: 79% excreted unchanged in urine via renal tubular secretion and glomerular filtration; 13% metabolized with 4% excreted in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion; <5% in feces.
Renal: sitagliptin ~87% unchanged in urine; metformin ~90% unchanged in urine. Biliary/fecal: minimal.
Category A/B
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor